WORCESTER, Mass., May 26, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced that its wholly owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be participating in the 2010 American Society of Clinical Oncology (ASCO) (www.asco.org) Annual Meeting in Chicago, Illinois June 4 through June 8 at McCormick Place.
With more than 30,000 cancer specialists attending to share their latest innovations in research, quality, practice and technology, the ASCO meeting will provide a platform for Antigen Express to spotlight its immunotherapeutics under development as a treatment modality that is more targeted and less toxic than conventional treatments for malignant, infectious, allergic, and autoimmune diseases.
"Therapeutic cancer vaccines are the future of cancer treatment," said Anna Gluskin, President & Chief Executive Officer of Generex. "Antigen Express continues to build an extraordinary portfolio of immunotherapeutics that is showing results in helping patients fight cancer cells. We look forward to sharing our findings at ASCO and to hearing what other breakthrough research is being done in this field."
New data from Antigen Express' lead immunotherapeutic AE37, a synthetic peptide vaccine designed to prevent the recurrence of a variety of different cancers that express the HER-2/neu protein, will be shared in a presentation by Guy Clifton of the abstract "Effect of a Novel Ii-Key Hybrid HER2/neu Peptide AE37 Vaccine with GM-CSF as Compared to GM-CSF Alone on Levels of Regulatory T-cell Treg Populations."
Antigen Express' new findings will build on the recently announced results from its Phase I study of AE37 in patients with prostate cancer, which support the safety and immunological activity of the vaccine and also show a decrease in the circulating levels of a fragment of the HER-2/neu protein.
In late 2009, Generex also announced encouraging interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The results showed no relapses in patients receiving the AE37 immunotherapeutic vaccine (0 of 49 patients), while relapses were observed in the control group (5 of 71 patients).
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, buccal insulin (Generex Oral-lyn™), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.